IGF and breast cancer: High circulating blood levels of insulin in women with high body surface area are associated with high insulin receptor expression in tissues such as muscle, fat, and tumor cells resistant to insulin, and this study found that reducing energy intake10 will reduce cancer development and attenuate the malignant behavior of tumor cells, and experimental data provide some evidence that if hosts increase energy intake will increase tumor cell growth, increasing Energy intake increases insulin levels in these models, and clinical studies provide further evidence that insulin or factors associated with its levels affect the prognosis of breast cancer, with rapidly increasing insulin levels and c-peptide levels at diagnosis having a poor prognosis, and in addition, it is commonly believed that breast cancer expresses the insulin receptor IGF-1, and in the underlying aspect it is proposed that insulin is a potential stimulus for breast cancer growth because Obesity and hyperinsulinemia are increasing social problems and this factor that affects public health and also breast cancer prognosis should be taken into account. Combination of vascular endothelial growth inhibitors and aromatase inhibitors: There is no more refreshing report than the preclinical study from Switzerland on the simultaneous inhibition of aromatase by the vascular endothelial growth factor inhibitor PTK787/ZK222584. Vascular endothelium is a key factor in breast cancer growth, infiltration and metastasis, clinical studies suggest that ER and VEGF signaling pathways may be related and that increased VEGF levels may be associated with endocrine resistance, and that simultaneous blockade of both pathways may increase the efficacy of therapy, and this meeting reported for the first time on this study, oral VEGFRPTK/ZK in vitro and in vivo models to study endocrine therapy for resistant and sensitive disease by culturing human breast cancer cell lines to express aromatase, MCF7-AROM1, MCF7-AROM3, PTK/ZK ± triamcinolone or letrozole, and evaluating the effect of the drug on aromatase, while dynamically observing changes in tumor neovascularization, and finding that PTK/ZK has an anti-aromatase in addition to an anti-angiogenic The results revealed that PTK/ZK has an anti-aromatase effect in addition to its anti-angiogenic effect, and this new finding may be one of the mechanisms for its therapeutic benefit. In conclusion, due to the emergence of endless targeted drugs, the treatment level of breast cancer will be further improved and a cure is expected, but the cost of treatment will also increase. We expect that the development of molecular biology technology will lead to more advancement in both treatment and diagnosis while also reducing costs so that patients can afford and enjoy the research results.